Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced results from a Phase 3 study investigating the safety
and efficacy of single-dose EMEND® (fosaprepitant
dimeglumine) for Injection, Merck’s substance P/neurokinin (NK-1)
receptor antagonist, in combination with other anti-vomiting medicines,
for the prevention of chemotherapy-induced nausea and vomiting (CINV) in
adult cancer patients receiving moderately emetogenic (vomit-inducing)
chemotherapy (MEC).
Language:
English
Contact:
MerckMedia:Doris Li, 908-740-1903orAn Phan, 908-255-6325orInvestor:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Merck | Neurology | Study